A phaseI,multiple-dose study of SA237

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221744

Enrollment

Registered

2012-03-19

Start date

2012-03-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

investigational material(s) Generic name etc : SA237 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigationa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients with rheumatoid arthritis of ≥ 6 months duration, diagnosed according to the revised 1987 ACR criteria - Patients with CRP > ULN at screening

Exclusion criteria

Exclusion criteria: - Any major episode of infection within 4 weeks prior to first dose - Active chronic hepatitis B and C - Active tuberculosis - Active interstitial pneumonia - History of serious allergic reactions

Design outcomes

Primary

Measure	Time frame
Safety, immunogenicity, PK/PD Observation/examination	—

Secondary

Measure	Time frame
Efficacy Observation/examination	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026